Diversity In Clinical Trials
We are here to advance inclusive research and health equity.
The experience of the global patient population widely varies based on sociodemographic characteristics. To deliver effective treatments broadly and inclusively, clinical trials must reflect diverse patient representation in all phases of the drug development process.
Embedding best practices representative of an end-to-end inclusive mindset will provide better treatments for a wider patient population. This is the commitment of the Diversity in Clinical Trials Steering Committee at Medidata.
Awareness, Access, and Data Power Greater Diversity in Clinical Trials
Awareness of Clinical Trials in Diverse Communities
Diversity in clinical research is both a scientific and ethical issue. Currently, drugs are still being approved and reaching the market with too little data relevant for minority communities.
In a review of 230 oncology clinical trials between 2008 and 2018, only 145 included any information about the participant’s race. Of those that did, approximately 76% of the participants were white, 18% Black, 3% Asian, and 6% Hispanic. Without data from all of these groups, we cannot be certain treatment will be safe and efficacious for the population intended to treat.
Diverse Patient Population Access to Clinical Trials
At Medidata, we are committed to ensuring that all patients have access to treatment by breaking barriers and challenging norms in order to improve access to comprehensive, quality services. With a concentration in diversity in clinical trials, drug repurposing, and patient advocacy we are creating a better world for patients.
Data-Driven Solutions to Reduce Racial Disparities in Clinical Trials
Through the Medidata Platform, we have the industry’s largest scientific and operational dataset.
We leverage this rich and granular dataset to help reduce disparity in terms of diversity in clinical trials to innovate data-driven solutions.
- We leverage data from 28,000+ clinical trials with 8M+ patients across nearly 150 countries
- Drill down from indication to site level to identify sites that disproportionately recruit diverse patients
- Compare to real world demographics in area and disease prevalence
Breaking Down Barriers to Health Equity
We Walk the Walk When it Comes to Diversity. Medidata continuously engages with diverse communities and government to actively drive change and improve the outreach of clinical trials awareness.
Our funding supports the production of Tu Salud, Tu Familia, a TV health program reaching 70,000 viewers every week in the D.C. Metro area. As part of our Social Innovation Lab, we created a customized Clinical Trial patient profile of the Emerson Clinic’s target demographic population and a heat map to identify high density underrepresented communities. As a result, Medidata has helped the Emerson Clinic increase access to care and patient participation in clinical trials by 30%.
Industry Thought Leaders
Our industry subject matter experts are dedicated to providing valuable data and insights to continue to improve diversity in clinical trials. Medidata recommends innovative strategies that leverage insights and technology solutions to address challenges in research, development, and commercial spaces.
Medidata actively reaches out to biotech, pharma, CRO, academia, other partners, institutions, organizations, and influencers to actively drive change.
In Partnership with SCRS, Medidata created a readiness assessment tool (DSAT) to help sites continually self-evaluate their capacity for recruiting and meeting the needs of diverse patient populations in clinical trials.
Diversity Site Assessment Tool
Medidata contributed significantly to the creation of the SCRS Diversity Site Assessment Tool (DSAT), a program to help sites consistently evaluate their practices in study enrollment and performance in order to pinpoint areas of opportunity to successfully facilitate inclusion and meet the needs of diverse patient populations in clinical trials.
There has not been significant progress to address the lack of diversity in clinical trial populations. This white paper, “Increasing Diversity in Clinical Trials”, explores technology investments and co-innovation with technology vendors will play a key role in enabling stakeholders to tackle the diversity challenge.
Walking the Talk
Watch the first of a series of discussions with industry thought leaders from Medidata, AbbVie, Emerson Clinical Research and Memorial Sloan Kettering Cancer Center as they share best practices on how to transform trials design, reduce patient burden, and build sustainable community relationships.
Decentralized Clinical Trials
Decentralized clinical trials can mitigate geographical and socio economic barriers for patient recruitment. Patients can access a broader range of available studies and improve diversity in clinical trials by participating in scientific research.
The Medidata Decentralized Clinical Trials program delivers the industry’s only scalable, end-to-end offering for trial decentralization that connects trial experiences for patients, sites, and sponsors.
Medidata’s Patient Insights program infuses the patient perspective into the software development life cycle to create technical solutions that improve the overall patient experience in clinical research operations.
myMedidata is a clinical research portal-for-life. Accessed using any web-enabled device, patients can use myMedidata to find, learn about, enroll and participate in all clinical trial activities from a single user interface.